GlassScriptPhysician profile
Myranda Prather
NPI 1275142903
$940.48
in general payments reported to CMS, 2019-2025
16 companies · $342 in 2025
The $342 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $98.83 · 2023: $319 · 2024: $181 · 2025: $342.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $823 · Education: $19.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $822.59 |
| Education | $19.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $172.83 | 2023-2024 | |
| Alexion Pharmaceuticals, INC. | $120.03 | 2025 | Ultomiris |
| Biogen, INC. | $119.68 | 2023 | Tysabri |
| Janssen Biotech, INC. | $82.27 | 2022-2024 | Stelara, Simponi Aria, Remicade |
| Genentech USA, INC. | $82.22 | 2024-2025 | Ocrevus Zunovo, Actemra |
| Abbvie INC. | $67.33 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $51.04 | 2024-2025 | Saphnelo |
| Octapharma USA, INC. | $47.85 | 2025 | Octagam Immune Globulin (Human) |
| Takeda Pharmaceuticals U.S.A., INC. | $41.93 | 2023-2025 | Elaprase, Hyqvia |
| Argenx US, INC. | $37.39 | 2025 | Vyvgart, Vyvgart Hytrulo |
| Lundbeck LLC | $28.25 | 2024 | Vyepti |
| Alnylam Pharmaceuticals INC. | $20.97 | 2022 | |
| Glaxosmithkline, LLC. | $20.47 | 2025 | Nucala |
| Celltrion USA INC. | $19.06 | 2024 | Zymfentra |
| Csl Behring | $15.08 | 2025 | Hizentra |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacosmos Therapeutics INC. | $14.08 | 2025 | Monoferric |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Myranda Prather listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.